Sorafenib联合重组人可溶性TRAIL蛋白对K562细胞增殖抑制和凋亡诱导的研究  

Sorafenib Combined with Recombinant Human TRAIL on Growth Inhibition Effects and Inducing Apoptosis of Leukemia Cells of K562

作　　者：王阿慧[1] 凌艳英[1] 庄秋容[1] 邓家德[1] 

机构地区：[1]广州医科大学附属广州市第一人民医院检验科血液室,广东广州510180

出　　处：《江汉大学学报（自然科学版）》2014年第2期64-69,共6页Journal of Jianghan University：Natural Science Edition

基　　金：广州市医药卫生科技项目(20131A011013)

摘　　要：目的观察比较联合应用重组人可溶性TRAIL蛋白及Sorafenib于人慢性髓系白血病细胞株K562与单独应用时细胞增殖抑制及诱导凋亡的差异。方法通过CCK-8法检测两者对K562细胞的增殖抑制作用;Western-Blot分析TRAIL或与Sorafenib联用对K562细胞的凋亡诱导作用。结果 Sorafenib与TRAIL联合作用于K562细胞时,其细胞的增殖抑制率及凋亡率均显著高于二者单独应用。结论 Sorafenib与TRAIL对K562细胞的增殖抑制及凋亡诱导有增敏及协同作用。Objective To investigate the different effect of Sorafenib and TRAIL on proliferationinhibition and apoptosis inducing of K562 cells.Methods Inhibition of K562 cells proliferationby Sorafenib alone and combined with TRAIL were studied in vitro using CCK-8. Apoptosis induc-ing rate of K562 cells by Sorafenib alone and combined with TRAIL were accessed by Western-Blotdetection.Results Combination with Sorafenib and TRAIL synergistically increased the growthinhibition effects and enhanced the apoptosis rate of K562 cells.Conclusion Combination treat-ment of Sorafenib and TRAIL showed a synergistic anti-proliferative effect in K562 cells.

关 键 词：索拉非尼 TRAIL 白血病细胞 细胞增殖抑制 细胞凋亡 

分 类 号：R730.54[医药卫生—肿瘤] R733.7[医药卫生—临床医学]